Title: Genomics of drug sensitivity in cancer
Abstract:
Outcomes of anticancer therapy vary dramatically among patients, which may be caused by the specific molecular alterations in each patient’s tumor. The development of ex vivo drug test-guided clinical response prediction platform has elicited clinical and industrial interests for precision cancer therapy. We have established a resource reporting the genomic and transcriptomic profiles of 462 patient tumor-derived cells across 14 cancer types, together with responses to 60 targeted agents. We identified molecular factors to induce resistance to EGFR inhibitors, and suggested repurposing ibrutinib for EGFR-specific therapy in gliomas. In addition, we discovered lineage-specific drug sensitivities based on subcategorization of gynecologic tumors. We also have manufactured an automated organo-spotter-integrated high throughput organo-on-pillar (High-TOP) drug test platform, demonstrating considerable robustness, consistency, reproducibility, and clinical relevancies in three-dimensional drug sensitivity analyses.
